Experience

Cardiff Oncology

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • Mar 2022 - Present



Washington University School of Medicine in St. Louis

• Hospitals and Health Care
• 700 & Above Employee

• Staff Scientist

  • Oct 2019 - Feb 2022

  • Evaluated a PARP-1 targeting radioligand for prostate cancer. • Established an in vivo metastatic prostate cancer (intracardiac injection) model. • Assessed the efficacy of the PARP-1 radioligand in cell line-derived xenograft mouse models. • Set up Luminex Guava Analyzer-based flow cytometry assays. • Supervised research technicians and trained a graduate student and postdoc. • Managed multiple collaborative projects (1 first author and 4 co-author publications). • Evaluated a PARP-1 targeting radioligand for prostate cancer. • Established an in vivo metastatic prostate cancer (intracardiac injection) model. • Assessed the efficacy of the PARP-1 radioligand in cell line-derived xenograft mouse models. • Set up Luminex Guava Analyzer-based flow cytometry assays. • Supervised research technicians and trained a graduate student and postdoc. • Managed multiple collaborative projects (1 first author and 4 co-author publications).



Gundersen Health System

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Fellow

  • Feb 2018 - Sep 2019

  • Prepared an antibody-drug conjugate targeting cleaved Amphiregulin (c-AREG) . • Evaluated c-AREG ADC in breast cancer cell lines and xenograft mouse models. • Characterized full length and c-AREG expression in a breast cancer tissue microarray (TMA). • Co-inventor (Patent Application #63211356) and co-first author of the manuscript. Techniques employed: Immunohistochemistry, MMAE conjugation of Ab, SDS-PAGE, ELISA, Live cell imaging (pHrodo conjugation), Viability and Survival assays, Lentiviral transduction for generating luciferase expressing cell lines, Tumor implantation and monitoring, In vivo bioluminescence imaging.



University of Pittsburgh

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Associate

  • 2013 - 2017

  • Identified differential proteasomal degradation of ER in Invasive lobular breast carcinoma (ILC) • Secured three-year postdoctoral funding from Susan G Komen foundation. • Evaluated the oral SERD AZD9496 in ILC tumor models (in collaboration with AstraZeneca). • Received ‘AACR-Scholar in training award’ for the study. • ‘Featured Article’ in Endocrinology (first author). • Mentored and trained undergraduate students. • Collaborations: MOA of Fulvestrant, and 3D breast cancer model ( 3 co-author articles). Techniques employed: Immunocytochemistry, FluoReporter™ proliferation assay, Cycloheximide chase, Western, qRT-PCR, Ubiquitination Pathway PCR-Array, immunoprecipitation and ubiquitination assay, Patient-derived primary cells from malignant effusions, Maintained patient derived xenograft (PDX) models, Survival Surgery Publications: 1. Endocrinology. 2020 Sep 161;Issue 9, bqaa109 (first author) 2. ACS Biomater Sci Eng. 2017; 4(2), 421-431. (co-author) 3. Mol Cell Endocrinol. 2015; 418:322-33. (co-author) 4. Mol Cell Endocrinol. 2015; 415:76-86. (co-author)